Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma

Table 6 Comparison of the literatures for helical tomotherapy in patients with unresectable hepatocellular carcinoma

Reference	No.	Fraction size (Gy)	Total dose (Gy)	Target of RT	Response (%)	Median Survival (months)	RILD (%)	Grade III toxicity	Combined therapy
McIntosh [19]	20	2.5	50	PVTT(+) 40 %	PR 6.2	9.6	N/A	UGI bleeding 1/20	Capecitabine
McIntosh [19]				PVTT(−) 60 %	SD 87.5
Chi [34]	23	2.5–4.5	52.5 (median)	N/A	CR 8.6	16	1/23	UGI bleeding 2/23	Sunitinib
Chi [34]					PR 65.4			Hematology 6/23
Kim [14]	35	4.5–6	50 (range, 45–60)	PVTT(+) 100 %	CR 14.3	12.9	0/35	GI bleeding 2/35	Capecitabine
					PR 28.6	Responder 13.9		Hematology 3/35
						Non-responder 6.9
Kong [15]	20	1.8–4	50–57.5 (range, 30–60)	PVTT(+) 36.4 %	CR 18.2	14.4	1/20	None	None
Kong [15]				PVTT(−) 63.6 %	PR 54.5	Responder 87.8^a
						Non-responder 65.6^a
Current study	38	1.8–2.4	54 (range, 46–71.8)	PVTT(+) 63.2 %	CR 5.2	12.6	1/38	1/38	None
Current study				PVTT(−) 36.5 %	PR 47.4	Responder 27.8
						Non-responder 6.2

RT radiation therapy, PVTT portal vein tumor thrombus, N/A no data, CR complete response, PR partial response, SD stable disease, RILD radiation-induced liver disease, GI gastrointestinal
^a1-year overall survival rate (%)

ISSN: 1477-7819